Psoriasis

Zusammenfassung

Die Psoriasis vulgaris ist eine chronische entzündliche Systemerkrankung. Ihre Entstehung ist multifaktoriell bedingt, mit einer starken genetischen Komponente. Etwa 20 Prozent der Psoriasispatienten erkranken auch an einer Psoriasis-Arthritis (PsA). Zusätzlich haben Psoriasispatienten ein erhöhtes Risiko für kardiovaskuläre Erkrankungen. Eine frühe Diagnosestellung und effektive Therapieeinleitung ist daher wichtig. Aufgrund der Komplexität der Erkrankung sollte ein interdisziplinäres Vorgehen aus Dermatologen, Rheumatologen und Internisten angestrebt werden

Summary

Psoriasis is a chronic inflammatory systemic disease. The development of the disease is multifactorial with a strong genetic component. About 20 % of psoriasis patients also develop psoriatic arthritis (PsA). Furthermore patients with psoriasis have a higher risk for cardiovascular diseases. Therefore an early diagnosis and a timely start of effective treatment is necessary. Because of the complexicity of the disease an interdisciplinary approach by dermatologists, rheumatologists and internists should be ensured.

Schlüsselwörter

Psoriasis vulgaris - Psoriasis-Arthritis - Spondyl arthritis

Keywords

Plaque-like psoriasis - psoriatic arthritis - spondyloarthritis

• Literatur

• 1 Nast A, Boehncke WH, Mrowietz U. German S3-guidelines on the treatment of psoriasis vulgaris (short version). Arch Dermatol Res 2012; 304: 87-113.
• 2 Puig L, Julia A, Marsal S. The Pathogenesis and Genetics of Psoriasis. Actas Dermosifiliogr. 2013 Jan 28.
• 3 Fitzgerald O, Winchester R. Psoriatic arthritis: from pathogenesis to therapy. Arthritis Res Ther 2009; 11: 214.
• 4 Gladman DD, Antoni C, Mease P. et al. Psoritic arthritis: epidemiology, clinical features, course, and outcome. Annals of the Rheumatic diseases 2005; 64 (02) ii14-ii17.
• 5 FitzGerald O, Winchester R. Psoriatic Arthritis: from pathogenesis to therapy. Arthritis Research & Therapy 2009; 11: 214.
• 6 Callis Duffin K, Chandran V, Gladman DD. et al. Genetics of Psoriasis and Psoriatic Arthritis: Update and Future Direction (GRAPPA 2007). Journal of Rheumatology 2008; 35 (07) 1449-1453.
• 7 Lloyd P, Ryan C, Menter A. Review Article. Psoriatic Arthritis: An Update. Arthritis 2012 Article ID 176298. doi:
• 8 Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. Annals of the Rheumatic Diseases 2005; 64 (II): ii3-ii8.
• 9 Poggenborg RP, Terslev L, Pedersen SJ, Ostergaard M. Recent advances in imaging in psoriatic arthritis. Therapeutic Advances in Musculoskeletal Disease 2011; 3 (01) 43-53.
• 10 Cuchacovich R, Perez-Alamino R, Garcia-Valladares I, Espinoza LR. Steps in the management of psoriatic arthritis: a guide for clinicians. Therapeutic Advances in Chronic Disease 2012; 3 (06) 259-269.
• 11 Ritchlin CT, Kavanaugh A, Gladman DD. et al. for GRAPPA Treatment recommendations for psoriatic arthritis. Annals of the Rheumatic Diseases 2009; 68: 1387-1394.
• 12 Puig L. Cardiovascular risk and psoriasis: the role of biologic therapy. Actas Dermosifiliogr 2012; 103: 853-862.
• 13 Gisondi P, Ferrazzi A, Girolomoni G. Metabolic comorbidities and psoriasis. Acta Dermatovenerol Croat 2010; 18: 297-304.
• 14 Vena GA, Vestita M, Cassano N. Psoriasis and cardiovascular disease. Dermatol Ther 2010; 23: 144-151.
• 15 Pietrzak A, Bartosinska J, Chodorowska G. et al. Cardiovascular aspects of psoriasis: an updated review. Int J Dermatol 2013; 52: 153-162.
• 16 De Simone C, Di Giorgio A, Sisto T. et al. Endothelial dysfunction in psoriasis patients: cross-sectional case-control study. Eur J Dermatol 2011; 21: 510-514.
• 17 Boehncke WH, Boehncke S, Tobin AM, Kirby B. The ‘psoriatic march’: a concept of how severe psoriasis may drive cardiovascular comorbidity. Exp Dermatol 2011; 20: 303-307.
• 18 Ghazizadeh R, Shimizu H, Tosa M, Ghazizadeh M. Pathogenic mechanisms shared between psoriasis and cardiovascular disease. Int J Med Sci 2010; 7: 284-289.
• 19 Wu JJ, Channual JC, Dann F. Association of systemic psoriasis therapies and incidence of myocardial infarction. Br J Dermatol 2012; 166: 232 author reply 233.
• 20 Geborek P, Bladstrom A, Turesson C. et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 2005; 64: 699-703.
• 21 Taylor W, Gladman D, Helliwell P. et al. CASPAR Study Group. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum 2006; 54: 2665-2673.